RECORD // Company

Atossa Therapeutics, Inc.

Formerly: ATOSSA GENETICS INC

Built 2026-11-22T01:01:08Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (1)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (4)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-10 · accession 0001193125-26-454468

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-5,638,0003 months ended 2026-09-3010-Q2026-11-100001193125-26-4544682026-11-22 01:01 UTCReport an error
Cash and cash equivalents$20,574,000at 2026-09-3010-Q2026-11-100001193125-26-4544682026-11-22 01:01 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001488039
Ticker
ATOS
EIN
264753208
Record ID
sx:sec:0001488039

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

23 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-10SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-10SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
State of incorporationDE2026-11-10SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
Fiscal year end (MMDD)12312026-11-10SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
Business address1448 NW MARKET STREET, SUITE 500, SEATTLE, WA, 981072026-11-10SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
ExchangesNasdaq2026-11-10SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-34,770,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 01:01 UTCReport an error
Total assets (at 2025-12-31)$47,608,0002025-12-3110-K, XBRL Assets2026-11-22 01:01 UTCReport an error
Stockholders' equity (at 2025-12-31)$39,353,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 01:01 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$41,299,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 01:01 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-29,762,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 01:01 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$23,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 01:01 UTCReport an error
Form D total offering amount (D filed 2013-04-11)$30,000,0002013-04-11D2026-11-22 01:01 UTCReport an error
Form D total amount sold (D filed 2013-04-11)$1,000,0002013-04-11D2026-11-22 01:01 UTCReport an error
Form D industry groupOther Health Care2013-04-11D2026-11-22 01:01 UTCReport an error
Form D revenue rangeDecline to Disclose2013-04-11D2026-11-22 01:01 UTCReport an error
Form D date of first sale2013-03-272013-04-11D2026-11-22 01:01 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-10)On November 10, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026 and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein…2026-11-10SEC EDGAR 8-K 0001193125-26-454486 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-09)On October 8, 2026, the Board of Directors (the “Board”) of Atossa Therapeutics, Inc. (the “Company”) declared a dividend of one stapled contingent value right (a “Stapled CVR”) for each share of the Company’s common stock, par value $0.18 per share (the “Common Stock”), outstanding at the close of business on October 19, 2026 (the “Record Date”), and authorized the issuance of one Stapled CVR with respect to each share of Common Stock that becomes outstanding after the Record Date and prior to the earlier of the detachment of the Stapled CVRs from the Common Stock and their expiration. The Stapled CVRs are governed by a Stapled Contingent Value Rights Agreement, dated as of October 8, 2026…2026-10-09SEC EDGAR 8-K 0001193125-26-418560 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 3.03, Material Modification to Rights of Security Holders (filed 2026-10-09)The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.2026-10-09SEC EDGAR 8-K 0001193125-26-418560 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-09)On October 9, 2026, the Company issued a press release announcing execution of the CVR Agreement and declaration of the Record Date. A copy of the related press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the Company’s potential eligibility for and receipt of a priority review voucher, the potential sale of any such voucher and the proceeds thereof, the amount and timing of any payment in respect of the Stapled CVRs, and any future detachment of the…2026-10-09SEC EDGAR 8-K 0001193125-26-418560 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-29)On September 29, 2026, Atossa Therapeutics, Inc. (the “Company”) announced that its board of directors has approved a plan to issue one contingent value right to each share of the Company’s common stock to enable stockholders to share in a portion of any proceeds received from the monetization of the Company’s first qualifying rare pediatric disease priority review voucher. A copy of the related press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.2026-09-29SEC EDGAR 8-K 0001193125-26-406036 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-09-18)On September 18, 2026, Atossa Therapeutics, Inc. (the “Company”) made available an updated corporate presentation, which is attached to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information in Items 7.01 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities…2026-09-18SEC EDGAR 8-K 0001193125-26-395694 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.